Ranfac Corp.
Ranfac Corporation, founded 1888 and family-owned, is a single-source CDMO/CMO for hypodermic-based Class I and II medical devices, operating a vertically integrated 40,000 sq. ft. facility in Avon, MA serving medical device OEMs worldwide.
- Company typePrivate
- Founded1888
- HeadquartersMaussane, France
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ranfac Corp. does
Ranfac Corporation is a privately held, family-owned medical device manufacturer founded in 1888 and headquartered at a 40,000 sq. ft. vertically integrated facility in Avon, Massachusetts. The company operates a single-source contract development and manufacturing platform for hypodermic-based Class I and II medical devices, covering metal machining (12 processes including Swiss-type CNC, laser and TIG welding, electropolishing, swaging, and ultrasonic cleaning), polymer insert and overmolding in a Class 8 cleanroom, Class 7 cleanroom assembly with ERP-tracked barcode traceability, and pre-validated ethylene oxide sterilization through an exclusive partnership with STERIS. Ranfac serves medical device OEMs across CDMO engagements (concept-to-cleared, including DFM and 510(k) / EU MDR technical-file support), CMO engagements (cleared-to-scaled), and proprietary OEM product sales.
The company's proprietary product portfolio is anchored by the patented SNARECOIL™ bone marrow biopsy needle family (8G-13G gauges, 2"-6" lengths with a captive specimen-capture mechanism), an RTN bone marrow biopsy variant, a General Surgery line including the IN-12 insufflation needle (FDA K930474), LAP-13 and XL-11 cholangiography catheters, RSG-14 puncture closure device, KPL-4 knot pusher ligator, and PIN-15 percutaneous introducer needle. In October 2023, Ranfac completed its first acquisition in 135 years by acquiring Cervos Medical, LLC., a developer of autologous tissue processing technologies for orthobiologic applications, which operates as a wholly owned subsidiary.
Ranfac generates revenue through multi-year CDMO/CMO contracts negotiated per project scope, volume, and regulatory complexity, plus unit-based pricing on proprietary OEM products. Customer acquisition runs on enterprise field sales with senior leadership direct engagement and industry referrals; named customers include Health Beacons (acquired by Hologic), ProAct (20+ year supplier relationship), BONESUPPORT, Zimmer Knee Creations, Integra, Anika Therapeutics, Hologic, and Varian. The firm holds ISO 13485:2016, MDSAP, EU MDR CE Mark, and FDA 21 CFR 820 registration, granting regulatory access to seven major markets (US, EU, UK, Canada, Japan, Australia, Brazil) from the single Avon facility.
Ranfac Corp. firmographics
Firmographics- Name
- Ranfac Corp.
- Legal name
- Ranfac Corporation
- Website
- https://ranfac.com
- Company type
- Private
- Founded year
- 1888
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Ranfac Corporation, founded 1888 and family-owned, is a single-source CDMO/CMO for hypodermic-based Class I and II medical devices, operating a vertically integrated 40,000 sq. ft. facility in Avon, MA serving medical device OEMs worldwide.
- Ownership category
- akta.pro rank
Ranfac Corp. industry classification
Industry- Product category
- Medical Device Contract Manufacturing
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
- akta.pro secondary industry
- GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where Ranfac Corp. is headquartered
LocationHeadquarters
- HQ city
- Maussane
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Ranfac Corp. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure
Revenue model
- CDMO Services: Full development cycle services for concept-to-clearance: DFM, process validation, regulatory submissions (510(k) support, EU MDR technical files), and scaled production under customer brand with complete design history file management.
- CMO/Manufacturing Services: High-volume, validated manufacturing for cleared device designs. Customers integrate into existing quality system or extend Ranfac's. Full traceability and real-time ERP visibility.
- OEM Product Sales: Proprietary portfolio of single-use hypodermic-based medical devices including SNARECOIL™ bone marrow biopsy needles, surgical instruments, and hematology products. Available for direct purchase or distribution.
- Cervos Medical (Subsidiary): Wholly owned subsidiary acquired October 2023. Develops autologous tissue processing technologies for orthobiologic applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | CDMO — Concept to Cleared |
| Other | Multi-year contract | CMO — Cleared to Scaled |
| Unit Pricing | Pay-as-you-go | OEM Products |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Ranfac Corp. product offering
Product offeringCore offering
Ranfac Corp. is a vertically integrated contract manufacturer (CDMO/CMO) of custom hypodermic-based medical devices, producing Class I and II sterile finished devices from raw metal and polymer under a single roof in Avon, MA. The company combines 12 precision metal machining processes, Class 8 cleanroom polymer molding, Class 7 cleanroom assembly, and pre-validated EO sterilization through STERIS into one continuous production system with a single quality system and one design history file. Ranfac also sells its own proprietary portfolio of minimally invasive devices, including the SNARECOIL™ bone marrow biopsy needle family and general surgery instruments.
Product overview
Ranfac Corp. is a vertically integrated medical device manufacturer offering custom hypodermic-based devices from raw material to sterile finished goods. The company operates a 40,000 sq. ft. single-facility in Avon, MA with capabilities spanning metal machining, polymer molding, cleanroom assembly, and EO sterilization. The proprietary product portfolio includes the SNARECOIL™ family of bone marrow biopsy needles (8G–13G, 2"–6" configurations) and a General Surgery product line (cholangiography catheters LAP-13 and XL-11, insufflation needle IN-12, puncture closure device RSG-14, knot pusher ligator KPL-4, and percutaneous introducer needle PIN-15). The company also offers CDMO and CMO contract manufacturing services. In October 2023, Ranfac acquired Cervos Medical LLC., a developer of autologous tissue processing technologies, operating as a wholly owned subsidiary. The manufacturing platform supports Class I and II devices with low minimum order quantities, scaling from first production runs to 500K+ units per year.
Differentiator
Problem solved
Functional benefit
Brands
- SNARECOIL™: Patented bone marrow biopsy needle product line featuring captive specimen-capture mechanism for long, non-fragmented core recovery. Available in 8G to 13G gauges and 2" to 6" lengths.
Products and services
- SNARECOIL™ Bone Marrow Biopsy Needle
- Knot Pusher Ligator (KPL-4)
- Percutaneous Introducer Needle (PIN-15)
- Puncture Closure Device (RSG-14)
- LAP-13 Cholangiography Catheter (Port Access)
- XL-11 Cholangiography Catheter (Percutaneous Access)
- IN-12 Insufflation Needle
- CDMO Services (Concept to Cleared)
- CMO Services (Cleared to Scaled)
- Cervos Medical (Wholly Owned Subsidiary)
Quantifiable outcome
- Manufacturing timeline accelerated 3-6 months through pre-validated STERIS sterilization partnership
- +2 more outcomes
Companies that use Ranfac Corp.
Customer profileNamed customers8 records
Segments6 records
Ideal customer profiles1 record
Ranfac Corp. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ranfac Corp. partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cervos Medical, LLCcoreWholly owned subsidiary acquired October 2023 as Ranfac's first acquisition in its 135-year history. Cervos Medical specializes in autologous tissue harvesting and processing technologies for the orthobiologic industry. Operates independently under Ranfac ownership, leveraging Ranfac's resources to expand product development and market reach.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Ranfac Corp. competitors and assessment
Company assessmentDirect peers
- Vygon: French-headquartered single-use medical device manufacturer specializing in IV access, neonatology, and surgical devices. Comparable vertically integrated single-use device business model with similar product categories, though focused on European clinical markets.
- Argon Medical Devices: Specialty medical device manufacturer focused on biopsy, drainage, and vascular access products. Comparable in scale and product mix to Ranfac's hematology and MIS access categories, with a similar mid-size OEM/private-equity-backed operating model.
- Tegra Medical: Medical device contract manufacturer specializing in precision metal and plastic components, surgical instruments, and finished device assembly. Highly comparable to Ranfac's metal machining plus molding integration, serving orthopedics, surgical, and interventional OEMs.
- Nordson Medical: Medical device component and contract manufacturing division of Nordson Corporation. Offers precision tubing, needles, and OEM device manufacturing directly comparable to Ranfac's metal machining and hypodermic capabilities.
- SMC Ltd. Privately held medical device contract manufacturer offering plastic molding, assembly, and sterile packaging. Comparable high-mix, low-to-mid volume CDMO model serving OEMs from concept through production, though without the in-house metal machining depth Ranfac offers.
- Integer Holdings: Pure-play medical device contract manufacturer offering design, manufacturing, and supply chain services for cardio, vascular, and surgical devices. Most directly comparable CDMO business model to Ranfac, though at significantly larger scale across multiple global facilities.
Broad incumbents
- ICU Medical: Major manufacturer of IV catheters, needle-free connectors, and safety hypodermic devices following its acquisition of Smiths Medical. Competes with Ranfac's hypodermic-based device portfolio, particularly in safety needles and infusion access.
- Becton Dickinson (BD): Largest global hypodermic needle and injection device manufacturer. BD's hypodermic, biopsy, and surgical product lines directly overlap with Ranfac's SNARECOIL portfolio; BD's Medical segment also operates a CDMO-style OEM services business.
- Teleflex: Global medical device manufacturer with a large hypodermic, biopsy, and surgical access portfolio. Overlaps with Ranfac's SNARECOIL biopsy needle and MIS access product categories, but operates at vastly larger scale across broader clinical segments.
Others
- STERIS (as adjacent enabler): Ranfac's exclusive EO sterilization partner. Not a competitor but a critical ecosystem enabler; STERIS's contract sterilization business and validation infrastructure is integral to Ranfac's pre-validated sterilization value proposition.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ranfac Corp. social profiles
Digital presenceRanfac Corp. compliance and trust
Trust signalCompliance5 records
Ranfac Corp. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ranfac Corp. leadership team
Management profileNumber of profiles
Profiles4 records
Ranfac Corp. subsidiaries and ownership
Company hierarchySubsidiaries1 record
Ranfac Corp. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ranfac Corp. M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ranfac Corp.
What does Ranfac Corp. do?
Ranfac Corp. is a vertically integrated contract manufacturer (CDMO/CMO) of custom hypodermic-based medical devices, producing Class I and II sterile finished devices from raw metal and polymer under a single roof in Avon, MA. The company combines 12 precision metal machining processes, Class 8 cleanroom polymer molding, Class 7 cleanroom assembly, and pre-validated EO sterilization through STERIS into one continuous production system with a single quality system and one design history file. Ranfac also sells its own proprietary portfolio of minimally invasive devices, including the SNARECOIL™ bone marrow biopsy needle family and general surgery instruments.
Is Ranfac Corp. a public or private company?
Ranfac Corp. is a private company. It is classified as family owned and is currently operating.
When was Ranfac Corp. founded?
Ranfac Corp. was founded in 1888. It employs 51 to 100 people.
Where is Ranfac Corp. based?
Ranfac Corp. is headquartered in Maussane, France, in the Europe region.
How does Ranfac Corp. make money?
Four revenue lines are on record. CDMO Services are the primary driver. The others are CMO/Manufacturing Services, OEM Product Sales and cervos Medical (Subsidiary).
Who are Ranfac Corp.'s main competitors?
Direct peers on record are Vygon, Argon Medical Devices, Tegra Medical, Nordson Medical, SMC Ltd. and Integer Holdings. Broad incumbents are ICU Medical, Becton Dickinson (BD) and Teleflex. STERIS (as adjacent enabler) is listed as an others.
Does Ranfac Corp. have an API?
No public API is recorded for Ranfac Corp..
What industry is Ranfac Corp. in?
Ranfac Corp.'s product category is Medical Device Contract Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification). Its NAICS code is 334510 and its SIC code is 3841.